On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) opened lower -0.02% from the last session, before settling in for the closing price of $41.55. Price fluctuations for IONS have ranged from $34.32 to $54.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13.97% over the last five years. Company’s average yearly earnings per share was noted -53.82% at the time writing. With a float of $133.94 million, this company’s outstanding shares have now reached $144.34 million.
The firm has a total of 927 workers. Let’s measure their productivity.
Ionis Pharmaceuticals Inc (IONS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ionis Pharmaceuticals Inc is 8.10%, while institutional ownership is 97.20%. The most recent insider transaction that took place on Feb 16 ’24, was worth 17,219. In this transaction Chief Executive Officer of this company sold 387 shares at a rate of $44.49, taking the stock ownership to the 173,751 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Executive Officer sold 23,501 for $49.37, making the entire transaction worth $1,160,303. This insider now owns 174,138 shares in total.
Ionis Pharmaceuticals Inc (IONS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -53.82% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Check out the current performance indicators for Ionis Pharmaceuticals Inc (IONS). In the past quarter, the stock posted a quick ratio of 5.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.35 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Analysing the last 5-days average volume posted by the [Ionis Pharmaceuticals Inc, IONS], we can find that recorded value of 0.88 million was lower than the volume posted last year of 1.16 million. As of the previous 9 days, the stock’s Stochastic %D was 10.22%. Additionally, its Average True Range was 1.11.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 2.12%, which indicates a significant decrease from 7.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.94% in the past 14 days, which was lower than the 31.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.64, while its 200-day Moving Average is $45.39. Now, the first resistance to watch is $41.89. This is followed by the second major resistance level at $42.25. The third major resistance level sits at $42.48. If the price goes on to break the first support level at $41.30, it is likely to go to the next support level at $41.07. Now, if the price goes above the second support level, the third support stands at $40.71.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
There are currently 145,752K shares outstanding in the company with a market cap of 6.05 billion. Presently, the company’s annual sales total 787,650 K according to its annual income of -366,290 K. Last quarter, the company’s sales amounted to 324,500 K and its income totaled -9,260 K.
